Prognostic value of liver stiffness measurement for complications after allogeneic transplant with post-transplant

Rebeca Bailén1,2, Manuel Fernández-Villalobos1, Sonia Alonso2,3

  • 1Department of Hematology and Hemotherapy, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Frontiers in Immunology
|February 9, 2026
PubMed

Insights

Liver stiffness (LS) measured by Fibroscan (FS) on day +14 post-allogeneic hematopoietic stem cell transplantation (HSCT) can predict transplant outcomes. A post-transplant FS value greater than 6 KPa is independently associated with worse event-free survival (EFS).

Area of Science:

  • Hepatology
  • Transplantation Medicine
  • Oncology

Background:

  • Pre-existing hepatic impairment impacts allogeneic hematopoietic stem cell transplantation (HSCT) outcomes.
  • Current prognostic scores like HCT-CI do not incorporate advanced liver assessment techniques.
  • Liver stiffness (LS) measurement is a modern, non-invasive method for evaluating liver health.

Purpose of the Study:

  • To evaluate the predictive value of LS using Fibroscan (FS) for transplant outcomes and hepatic complications in patients undergoing allo-HSCT.
  • To assess the utility of LS measurements taken before and after transplantation.
  • To determine if LS can improve prognostic models for HSCT outcomes, particularly with post-transplant cyclophosphamide (PTCY) GVHD prophylaxis.

Main Methods:

  • Prospective, observational, single-center study from October 2021 to March 2024.
  • LS measured by FS pre-transplant and on day +14 post-transplant.
  • Receiver operating characteristic (ROC) curves and logistic regression analyzed LS impact on survival, mortality, GVHD, and VOD.

Main Results:

  • One hundred eight patients included; median follow-up 12.5 months.
  • Increased LS variation (FSΔ) from baseline to day +14 predicted VOD development (p=0.048).
  • FS on day +14 > 6 KPa predicted worse overall survival (OS) and event-free survival (EFS) in univariate analysis, and worse EFS in multivariate analysis.

Conclusions:

  • LS measured by FS on day +14 is predictive of VOD.
  • A post-transplant FS value > 6 KPa is an independent predictor of worse EFS after allo-HSCT.
  • FS+14>6 KPa should be incorporated into future prognostic models for PTCY-based HSCT.
Abstract

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.1K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
494
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.3K
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
436
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
405
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
928